Abstract

EVALUATING THE POTENTIAL OF INSULIN ICODEC IN DIABETES MANAGEMENT

Rohit Singh Deo*, Agnes Sara Shibu, Dr. Rajesh Kumar Singh and Dr. Sajidul Hoque

ABSTRACT

Objectives: This paper examines the development, pharmacological properties, and clinical applications of insulin Icodec, an ultralong-acting analogue for once-weekly subcutaneous administration. It also aimed to evaluate the safety, efficacy, and advantages in managing type 1 and type 2 diabetes, emphasizing glycaemic control and reduced hypoglycaemia risk. Methods: The Novo Nordisk product Insulin Icodec was examined by means of a thorough analysis of information obtained from peer-reviewed publications, particularly information that described its safety, efficacy, and pharmacokinetic characteristics. Reduced insulin receptor affinity and improved albumin-binding capabilities are the causes of the unique 196-hour half-life. We conducted a thorough search of the Cochrane Library, Scopus, ClinicalTrials.gov, and Medline databases. This review included scientific studies that compared insulin Icodec with basal insulin. Results: Clinical studies revealed the effectiveness of insulin Icodec in achieving glycaemic control comparable to that of existing analogues with a lower risk of hypoglycaemia. The once-weekly dosage aligns with patient preferences, potentially improving adherence. Safety profiles are akin to those of other long-acting analogues, with modest side effects. Conclusions: Insulin Icodec is a promising alternative for diabetes management, that offers an extended half-life and convenient dosing. Its unique pharmacokinetic profile, efficacy, and safety suggest transformative implications. Future research should focus on long-term effects, patient satisfaction, and real-world applicability to confirm its role in diabetes treatment. 

Keywords: Insulin Icodec; Ultra long-acting insulin analogue; Pharmacokinetics; Glycaemic control; Diabetes management.